Dr Reddys Laboratories (RDY) Revenue (2009 - 2023)

Dr Reddys Laboratories (RDY) has reported Revenue for 15 consecutive years, with $828.0 million the latest figure, recorded in Q2 2023.

• Quarterly Revenue changed N/A year-over-year to $828.0 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $824002.4 billion (changed N/A YoY) and the FY2026 annual result came in at $3.6 billion, down 6.06% from the prior year.
• Revenue grew to $828.0 million in Q2 2023 per RDY's latest filing, from $811.0 million in the prior quarter.
• Over the last five years, Revenue for RDY reached as high as $824000.0 billion in Q3 2022 and fell as low as $544.0 million in Q1 2019.
• A 5-year average of $68667.3 billion and a median of $674.0 million in 2019 frame the typical range for Revenue.
• Annual changes were most pronounced in 2019 — Revenue advanced 28.44% — and 2020, when it decreased 0.3%.
• Year by year, Revenue stood at $614.0 million in 2019, then increased by 9.93% to $675.0 million in 2020, then gained by 15.11% to $777.0 million in 2021, then slipped by 1.29% to $767.0 million in 2022, then grew by 7.95% to $828.0 million in 2023.
• According to Business Quant data, Revenue over the past three periods registered $828.0 million, $811.0 million, and $767.0 million for Q2 2023, Q1 2023, and Q4 2022 respectively.